Arcus Biosciences (RCUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Voting matters and shareholder proposals
Election of four directors: Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier, with board recommending a vote for each nominee.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation as disclosed in the proxy statement.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting scheduled for June 11, 2026.
Audit committee and external auditor matters
Audit Committee has selected Ernst & Young LLP as the external auditor for the upcoming fiscal year, subject to shareholder ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcus Biosciences
- Virtual meeting to vote on directors, auditor, and executive pay, with strong governance and Gilead ties.RCUS
Proxy filing21 Apr 2026 - Casdatifan and quemliclustat drive late-stage pipeline toward major 2026 milestones and markets.RCUS
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Casdatifan achieved 45% ORR and 15.1-month PFS in RCC, with $1B cash supporting pipeline growth.RCUS
Q4 20258 Apr 2026 - Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data.RCUS
Leerink Global Healthcare Conference 20269 Mar 2026 - Phase III studies advance in gastric and RCC, with pivotal data and market expansion expected soon.RCUS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q2 revenue rose to $39M, $1.0B cash funds late-stage oncology trials into 2027.RCUS
Q2 20241 Feb 2026 - Upcoming data for AB521 and Domvanalimab highlight strong clinical momentum and strategic flexibility.RCUS
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Key data for HIF-2 alpha and TIGIT programs expected soon, with strong market and pipeline momentum.RCUS
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Key data for HIF-2 alpha and TIGIT programs expected soon, driving confidence and growth.RCUS
2024 Cantor Global Healthcare Conference20 Jan 2026